Keio University · Medicine
Professor Katsunori Masaki's research lab focuses on digital health interventions for chronic disease management, particularly digital therapies for smoking cessation using smartphone applications and mobile monitoring tools. The lab also investigates respiratory and immune-mediated diseases, including the impact of viral burden on symptoms in SARS-CoV-2 infection and adverse pulmonary reactions to biologic therapies like dupilumab. Additionally, the lab explores the immunological mechanisms underlying allergic inflammation, particularly the dual role of IL-23 in allergic sensitization versus airway inflammation. These interdisciplinary efforts integrate clinical medicine, immunology, and digital technology to improve patient outcomes in respiratory and inflammatory conditions.
Figures are computed from collected data and may differ slightly.
Evidence of the long-term efficacy of digital therapies for smoking cessation that include a smartphone application (app) is limited. In this multi-center randomized controlled trial, we tested the efficacy of a novel digital therapy for smoking cessation: the "CureApp Smoking Cessation (CASC)" system, including a CASC smartphone app, a web-based patient management PC software for primary physicians, and a mobile exhaled carbon monoxide (CO) checker. A total of 584 participants with nicotine dep
The addition of CASC to usual smoking cessation therapies resulted in high CARs, high patient retention rates, and improvement of cessation-related symptoms. The smartphone app CASC is a feasible and useful tool to help long-term continuous abstinence that can be combined with a standard smoking cessation treatment program.
This study investigated, using cycle threshold (Ct) qPCR values, the association between symptoms and viral clearance in 57 patients with asymptomatic/mild SARS-CoV-2 infection. Patients with olfactory/taste disorders (OTDs) exhibited lower qPCR Ct values and longer time to negative qPCR than those without OTDs, suggesting an association between OTDs and high viral burden.
Reports of eosinophilic pneumonia (EP) as a side effect of dupilumab administration are limited in previous studies. Herein, we report two cases in which EP developed subsequent to the administration of dupilumab for eosinophilic chronic rhinosinusitis (ECRS). Case 1: A 55-year-old woman presented with ECRS, eosinophilic otitis media, and bronchial asthma, and was treated with dupilumab for ECRS. Five weeks later, fever and dyspnea developed, and infiltration shadows were observed in her lungs.
Cumulative smoking exposure was positively associated with COVID-19 outcomes in smokers.
A 56-year-old woman presented with repeated swelling of the lips and face. She had a history of childhood asthma; she had a recurrence of asthma when she was 54 years old and was taking inhaled corticosteroids, and other antiasthma drugs. The swelling of her lips and face improved temporarily with oral corticosteroids (OCS), but recurred soon after discontinuing OCS. Her peripheral blood eosinophil count was 632/μL (9.3%), and her serum was negative for myeloperoxidase-anti-neutrophil cytoplasmi
IL-23 expressed in the skin during the sensitization phase plays an essential role in the development of allergic phenotypes, whereas IL-23 in the airways during the challenge phase suppresses airway hyperresponsiveness.
Repetitive instructions at shorter intervals may be helpful for patients to develop and maintain an improved inhalation technique.
Open papers in the app to read, cite, and organize with AI.
